{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:17:53Z","timestamp":1791328673463,"version":"4.3.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Astellas Pharma Global Development, Inc."},{"name":"Theravance, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.ijantimicag.2010.05.016","type":"journal-article","created":{"date-parts":[[2010,7,5]],"date-time":"2010-07-05T08:10:51Z","timestamp":1278317451000},"page":"374-379","source":"Crossref","is-referenced-by-count":26,"title":["Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007\u20132008)"],"prefix":"10.1016","volume":"36","author":[{"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2010.05.016_bib1","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1086\/533590","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus","volume":"46","author":"Boucher","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0924-8579(03)00154-7","article-title":"Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy","volume":"22","author":"Jones","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib4","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2010.05.016_bib5","first-page":"ii65","article-title":"Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001\u201306","volume":"62","author":"Hope","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jac\/dkn124","article-title":"In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004\u201305 Prospective European Surveillance Initiative","volume":"62","author":"Draghi","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib7","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1128\/AAC.01641-07","article-title":"Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States","volume":"52","author":"Draghi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2010.05.016_bib8","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.1086\/533594","article-title":"Pneumonia caused by methicillin-resistant Staphylococcus aureus","volume":"46","author":"Rubinstein","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib9","unstructured":"VIBATIV\u2122 (telavancin) for injection (package insert). Theravance, Inc. and Astellas Pharma Global Development, Inc. http:\/\/www.vibativ.com [accessed 28 May 2010]."},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib10","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.01710-08","article-title":"Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II","volume":"53","author":"Lunde","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib11","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M07-A8. Wayne, PA: CLSI; 2009."},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib12","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010."},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib13","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical MIC breakpoints. http:\/\/www.eucast.org\/clinical_breakpoints [accessed 1 June 2010]."},{"key":"10.1016\/j.ijantimicag.2010.05.016_bib14","series-title":"18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 19\u201322 April 2008, Barcelona, Spain","article-title":"Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies","author":"Rubenstein","year":"2008"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910002359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910002359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T19:41:58Z","timestamp":1588794118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857910002359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0924857910002359"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.05.016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}